Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

Jerry S. Lanchbury net worth and biography

Jerry Lanchbury Biography and Net Worth

Insider of Myriad Genetics

Jerry Lanchbury, chief scientific officer, joined Myriad Genetics in September 2002. Before that, he was a researcher in molecular immunogenetics at Kings College London. He is a highly respected expert in immunogenetics with more than 100 reviewed research journal publications. Dr. Lanchbury graduated from the University of Aston, Birmingham, U.K. He earned his Ph.D. in Population Genetics from the University of Newcastle upon Tyne and subsequently completed a postdoctoral fellowship at the United Medical & Dental Schools of the University of London in Human Disease Genetics.

What is Jerry S. Lanchbury's net worth?: The estimated net worth of Jerry S. Lanchbury is at least $4.49 million as of August 23rd, 2021. Dr. Lanchbury owns 242,550 shares of Myriad Genetics stock worth more than $4,487,175 as of April 19th. This net worth evaluation does not reflect any other investments that Dr. Lanchbury may own. Learn More about Jerry S. Lanchbury's net worth.
How do I contact Jerry S. Lanchbury?: The corporate mailing address for Dr. Lanchbury and other Myriad Genetics executives is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. Myriad Genetics can also be reached via phone at (801) 584-3600 and via email at [email protected]. Learn More on Jerry S. Lanchbury's contact information.
Has Jerry S. Lanchbury been buying or selling shares of Myriad Genetics?: Jerry S. Lanchbury has not been actively trading shares of Myriad Genetics within the last three months. Most recently, Jerry S. Lanchbury sold 200 shares of the business's stock in a transaction on Thursday, September 23rd. The shares were sold at an average price of $35.06, for a transaction totalling $7,012.00. Learn More on Jerry S. Lanchbury's trading history.
Who are Myriad Genetics' active insiders?: Myriad Genetics' insider roster includes Jayne Hart (Insider), Nicole Lambert (Insider), Jerry Lanchbury (Insider), Dennis Langer (Director), S. Phanstiel (Director), Richard Riggsbee (CFO), and Daniel Spiegelman (Director). Learn More on Myriad Genetics' active insiders.
Are insiders buying or selling shares of Myriad Genetics?: In the last twelve months, insiders at the sold shares 2 times. They sold a total of 38,638 shares worth more than $669,460.38. The most recent insider tranaction occured on November, 1st when CFO Richard Bryan Riggsbee sold 30,000 shares worth more than $470,700.00. Insiders at Myriad Genetics own 2.0% of the company. Learn More about insider trades at Myriad Genetics.
Information on this page was last updated on 11/1/2023.

Jerry S. Lanchbury Insider Trading History at Myriad Genetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/23/2021	Sell	200	$35.06	$7,012.00
8/23/2021	Sell	50,000	$35.17	$1,758,500.00	242,550
8/5/2021	Sell	28,225	$35.57	$1,003,963.25	260,775
8/3/2021	Sell	50,000	$34.03	$1,701,500.00
7/13/2021	Sell	43,295	$33.74	$1,460,773.30	269,255
7/9/2021	Sell	50,000	$32.62	$1,631,000.00	259,255
7/7/2021	Sell	32,308	$32.27	$1,042,579.16	262,974
6/28/2021	Sell	6,812	$32.39	$220,640.68	236,523
6/25/2021	Sell	83,372	$31.96	$2,664,569.12	287,282
5/4/2021	Sell	19,360	$31.97	$618,939.20	285,282
4/27/2021	Sell	40,000	$31.47	$1,258,800.00	305,922
2/16/2021	Sell	80,000	$29.71	$2,376,800.00	321,020
6/18/2018	Sell	60,000	$40.12	$2,407,200.00	196,463
10/28/2015	Sell	50,962	$41.86	$2,133,269.32	70,737
10/27/2015	Sell	24,767	$41.80	$1,035,260.60	70,737
9/17/2015	Sell	60,270	$39.89	$2,404,170.30	70,737
10/4/2012	Sell	3,900	$28.50	$111,150.00
10/3/2012	Sell	3,000	$28.50	$85,500.00

Jerry S. Lanchbury Buying and Selling Activity at Myriad Genetics

Myriad Genetics Company Overview

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $18.50

$18.25

$18.69

50 Day Range

MA: $21.54

$18.50

$23.59

2 Week Range

Now: $18.50

$13.82

$24.21

Volume

487,827 shs

Average Volume

626,910 shs

Market Capitalization

$1.66 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.95

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad